- Home
- JHG vs ALKS Comparison
JHG vs ALKS Comparison
Compare JHG & ALKS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JHG
- ALKS
- Stock Information
- Founded
- JHG 1934
- ALKS 1987
- Country
- JHG United Kingdom
- ALKS Ireland
- Employees
- JHG N/A
- ALKS N/A
- Industry
- JHG Investment Managers
- ALKS Biotechnology: Pharmaceutical Preparations
- Sector
- JHG Finance
- ALKS Health Care
- Exchange
- JHG Nasdaq
- ALKS Nasdaq
- Market Cap
- JHG 4.7B
- ALKS 4.8B
- IPO Year
- JHG N/A
- ALKS 1991
- Fundamental
- Price
- JHG $36.32
- ALKS $30.84
- Analyst Decision
- JHG Buy
- ALKS Buy
- Analyst Count
- JHG 11
- ALKS 13
- Target Price
- JHG $41.27
- ALKS $38.85
- AVG Volume (30 Days)
- JHG 1.5M
- ALKS 1.6M
- Earning Date
- JHG 05-01-2025
- ALKS 07-23-2025
- Dividend Yield
- JHG 4.40%
- ALKS N/A
- EPS Growth
- JHG N/A
- ALKS N/A
- EPS
- JHG 2.52
- ALKS 2.09
- Revenue
- JHG $2,542,900,000.00
- ALKS $1,513,770,000.00
- Revenue This Year
- JHG $3.95
- ALKS N/A
- Revenue Next Year
- JHG $5.02
- ALKS $4.11
- P/E Ratio
- JHG $14.44
- ALKS $14.52
- Revenue Growth
- JHG 17.85
- ALKS N/A
- 52 Week Low
- JHG $28.26
- ALKS $22.90
- 52 Week High
- JHG $46.68
- ALKS $36.45
- Technical
- Relative Strength Index (RSI)
- JHG 50.44
- ALKS 47.14
- Support Level
- JHG $35.64
- ALKS $29.20
- Resistance Level
- JHG $37.36
- ALKS $30.57
- Average True Range (ATR)
- JHG 0.69
- ALKS 0.70
- MACD
- JHG -0.18
- ALKS -0.10
- Stochastic Oscillator
- JHG 21.38
- ALKS 27.54
About JHG Janus Henderson Group plc
Janus Henderson Group provides investment management services to retail intermediary (56% of managed assets), self-directed (23%) and institutional (21%) clients. At the end of September 2024, active equities (63%), fixed-income (21%), multi-asset (14%) and alternative (2%) investment platforms constituted the company's $382.3 billion in assets under management. Janus Henderson sources most of its managed assets from clients in North America (61%), with customers from Europe, the Middle East, Africa, and Latin America (29%) and the Asia-Pacific region (10%) accounting for the remainder.
About ALKS Alkermes plc
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.